Allergic bronchopulmonary aspergillosis--a clinical review

Allergic bronchopulmonary aspergillosis--a clinical review

Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and rad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Association of Physicians of India 2012-04, Vol.60, p.46-51
Hauptverfasser: Gupta, Rajesh Kumar, Chandr, Amol, Gautam, Praveen Bahadur
Format: Artikel
Sprache:eng
Schlagworte:
Adrenal Cortex Hormones - therapeutic use
Antifungal Agents - therapeutic use
Aspergillosis, Allergic Bronchopulmonary - diagnosis
Aspergillosis, Allergic Bronchopulmonary - drug therapy
Aspergillosis, Allergic Bronchopulmonary - epidemiology
Humans
Itraconazole - therapeutic use
Prognosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.
ISSN:0004-5772